ServicenavigationHauptnavigationTrailKarteikarten


Research unit
EU RFP
Project number
00.0218
Project title
TARGETED GENE VECTOR: Targeted vectors for cancer gene therapy: receptor and transcriptional targeting of retroviral, lentiviral and adenoviral vectors.

Texts for this project

 GermanFrenchItalianEnglish
Key words
-
-
-
Anzeigen
Alternative project number
-
-
-
Anzeigen
Research programs
-
-
-
Anzeigen
Short description
-
-
-
Anzeigen
Further information
-
-
-
Anzeigen
Partners and International Organizations
-
-
-
Anzeigen
Abstract
-
-
-
Anzeigen
References in databases
-
-
-
Anzeigen

Inserted texts


CategoryText
Key words
(English)
Retroviral vectors; lentiviral vectors; adenoviral vectors
Alternative project number
(English)
EU project number: QLK3-1999-00364
Research programs
(English)
EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'
Short description
(English)
See abstract
Further information
(English)
Full name of research-institution/enterprise:
Université de Genève
Département de Génétique et Microbiologie
CMU
Partners and International Organizations
(English)
Coordinator: Université Pierre et Marie Curie (F)
Abstract
(English)
Our laboratory developed lentiviral vectors, a new gene delivery system that offers great promises for human gene therwpy. Within the framework of this european project, we proposed to develop further and optimize lentiviral vector-based techniques for the transfer of genes into the liver. Over the last year we demonstrated that a so-called third-generation HIV-derived vector system can govern the efficient delivery, integration and stable expression of a transgene into primary human hepatocytes in the complete absence of cell division. We also showed that rat and mouse hepatocytes are significantly resistant to HIV vector-mediated transduction due to a block in the immediate-early phase of infection, an important shortcoming of rodent models for the preclinical assessment of this therapeutic tool. We finally described a methodology that allows very high rates of transduction through minimal in vitro manipulation, in which hepatocytes are kept in suspension and re-implanted within a few hours of harvest with a fully preserved engraftment potential. These results have immediate implications for the treatment of liver diseases via the transplantation of genetically modified hepatocytes, an approach that could be applied to a number of hereditary and acquired hepatic disorders.
References in databases
(English)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 00.0218